Nicolas Poirier
Chief Executive Officer bij OSE IMMUNOTHERAPEUTICS
Vermogen: 1 M $ op 31-03-2024
Profiel
Nicolas Poirier is currently the Chief Executive Officer & Director at OSE Immunotherapeutics SA since 2022.
Previously, he worked as a Project Manager at Effimune SA. Dr. Poirier has a graduate degree from the University of Nantes and Louis Pasteur University, and an undergraduate degree from the Centre d'Etudes Supérieures de Techniques Industrielles.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-12-2022 | 192 802 ( 0.89% ) | 1 M $ | 31-03-2024 |
Actieve functies van Nicolas Poirier
| Bedrijven | Functie | Begin |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Chief Executive Officer | 07-10-2022 |
Eerdere bekende functies van Nicolas Poirier
| Bedrijven | Functie | Einde |
|---|---|---|
Effimune SA
 Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Corporate Officer/Principal | - |
Opleiding van Nicolas Poirier
| University of Nantes | Graduate Degree |
| Centre d'Etudes Supérieures de Techniques Industrielles | Undergraduate Degree |
| Louis Pasteur University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Effimune SA
Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Health Technology |
